Global Recombinant Human Serum Albumins Market

Recombinant Human Serum Albumins Comprehensive Study by Type (OsrHSA, ScrHSA), Application (Drug Formulation, Pharmaceuticals, Diagnostics, Coating of Medical Devices, Vitro Fertilization, Cosmetic, Others), End-Use (Hospitals, Clinics, Biopharming) Players and Region - Global Market Outlook to 2027

Recombinant Human Serum Albumins Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Human serum albumin (HSA) is the richest protein found in human blood plasma which is produced in the liver. The biological purposes of albumin include and transportation & metabolization of endogenous, normalization of the colloidal osmotic blood pressure and exogenous molecules e.g. fatty acids, amino acids, steroids, hormones, and pharmaceutical drugs. rHSA is plant-derived (rice-based), which reduces the risk of bacterial and viral infections. Additionally, the greater consistency of rHSA saves time while providing better performance. The annual demand for therapeutic human serum albumin (HSA) is predictable to be more than 500 metric tons worldwide. As a major protein in the human body, HSA plays a vital role in many physiological processes, including the maintenance of oncotic pressure and the transportation of various biomolecules and pharmaceuticals.This growth is primarily driven by Risk of Transmission of Viruses and Infectious Due to Use of pHSA and Increasing Plasma Collection.

Globally, a noticeable market trend is evident Increasing Non-Therapeutic Application of Albumin. Major Players, such as Albumedix (United Kingdom), Merck (United States), Ventria (InVitria) (United States), Proteintech Group (United States), Wuhan Healthgen Biotechnology Corp. (China), HiMedia Laboratories (India), Biorbyt Ltd. (United Kingdom), Aspira Chemical (United States) and Lazuline (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Risk of Transmission of Viruses and Infectious Due to Use of pHSA
  • Increasing Plasma Collection

Market Trend
  • Increasing Non-Therapeutic Application of Albumin

Restraints
  • Stringent Government Regulations on Human Serum Albumin

Opportunities
High Demand for Albumin in R&D Activities and Expanding Applications of Albumin
Challenges
High Competition from Substitute Products

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Recombinant Human Serum Albumins Study Sheds Light on
— The Recombinant Human Serum Albumins Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Recombinant Human Serum Albumins industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Recombinant Human Serum Albumins industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • OsrHSA
  • ScrHSA
By Application
  • Drug Formulation
  • Pharmaceuticals
  • Diagnostics
  • Coating of Medical Devices
  • Vitro Fertilization
  • Cosmetic
  • Others
By End-Use
  • Hospitals
  • Clinics
  • Biopharming

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Risk of Transmission of Viruses and Infectious Due to Use of pHSA
      • 3.2.2. Increasing Plasma Collection
    • 3.3. Market Challenges
      • 3.3.1. High Competition from Substitute Products
    • 3.4. Market Trends
      • 3.4.1. Increasing Non-Therapeutic Application of Albumin
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant Human Serum Albumins, by Type, Application, End-Use and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Recombinant Human Serum Albumins (Value)
      • 5.2.1. Global Recombinant Human Serum Albumins by: Type (Value)
        • 5.2.1.1. OsrHSA
        • 5.2.1.2. ScrHSA
      • 5.2.2. Global Recombinant Human Serum Albumins by: Application (Value)
        • 5.2.2.1. Drug Formulation
        • 5.2.2.2. Pharmaceuticals
        • 5.2.2.3. Diagnostics
        • 5.2.2.4. Coating of Medical Devices
        • 5.2.2.5. Vitro Fertilization
        • 5.2.2.6. Cosmetic
        • 5.2.2.7. Others
      • 5.2.3. Global Recombinant Human Serum Albumins by: End-Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Biopharming
      • 5.2.4. Global Recombinant Human Serum Albumins Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Recombinant Human Serum Albumins (Volume)
      • 5.3.1. Global Recombinant Human Serum Albumins by: Type (Volume)
        • 5.3.1.1. OsrHSA
        • 5.3.1.2. ScrHSA
      • 5.3.2. Global Recombinant Human Serum Albumins by: Application (Volume)
        • 5.3.2.1. Drug Formulation
        • 5.3.2.2. Pharmaceuticals
        • 5.3.2.3. Diagnostics
        • 5.3.2.4. Coating of Medical Devices
        • 5.3.2.5. Vitro Fertilization
        • 5.3.2.6. Cosmetic
        • 5.3.2.7. Others
      • 5.3.3. Global Recombinant Human Serum Albumins by: End-Use (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Biopharming
      • 5.3.4. Global Recombinant Human Serum Albumins Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Recombinant Human Serum Albumins (Price)
      • 5.4.1. Global Recombinant Human Serum Albumins by: Type (Price)
  • 6. Recombinant Human Serum Albumins: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Albumedix (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ventria (InVitria) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Proteintech Group (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Wuhan Healthgen Biotechnology Corp. (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. HiMedia Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biorbyt Ltd. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aspira Chemical (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lazuline (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Recombinant Human Serum Albumins Sale, by Type, Application, End-Use and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Recombinant Human Serum Albumins (Value)
      • 7.2.1. Global Recombinant Human Serum Albumins by: Type (Value)
        • 7.2.1.1. OsrHSA
        • 7.2.1.2. ScrHSA
      • 7.2.2. Global Recombinant Human Serum Albumins by: Application (Value)
        • 7.2.2.1. Drug Formulation
        • 7.2.2.2. Pharmaceuticals
        • 7.2.2.3. Diagnostics
        • 7.2.2.4. Coating of Medical Devices
        • 7.2.2.5. Vitro Fertilization
        • 7.2.2.6. Cosmetic
        • 7.2.2.7. Others
      • 7.2.3. Global Recombinant Human Serum Albumins by: End-Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Biopharming
      • 7.2.4. Global Recombinant Human Serum Albumins Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Recombinant Human Serum Albumins (Volume)
      • 7.3.1. Global Recombinant Human Serum Albumins by: Type (Volume)
        • 7.3.1.1. OsrHSA
        • 7.3.1.2. ScrHSA
      • 7.3.2. Global Recombinant Human Serum Albumins by: Application (Volume)
        • 7.3.2.1. Drug Formulation
        • 7.3.2.2. Pharmaceuticals
        • 7.3.2.3. Diagnostics
        • 7.3.2.4. Coating of Medical Devices
        • 7.3.2.5. Vitro Fertilization
        • 7.3.2.6. Cosmetic
        • 7.3.2.7. Others
      • 7.3.3. Global Recombinant Human Serum Albumins by: End-Use (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Biopharming
      • 7.3.4. Global Recombinant Human Serum Albumins Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Recombinant Human Serum Albumins (Price)
      • 7.4.1. Global Recombinant Human Serum Albumins by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant Human Serum Albumins: by Type(USD Million)
  • Table 2. Recombinant Human Serum Albumins OsrHSA , by Region USD Million (2016-2021)
  • Table 3. Recombinant Human Serum Albumins ScrHSA , by Region USD Million (2016-2021)
  • Table 4. Recombinant Human Serum Albumins: by Application(USD Million)
  • Table 5. Recombinant Human Serum Albumins Drug Formulation , by Region USD Million (2016-2021)
  • Table 6. Recombinant Human Serum Albumins Pharmaceuticals , by Region USD Million (2016-2021)
  • Table 7. Recombinant Human Serum Albumins Diagnostics , by Region USD Million (2016-2021)
  • Table 8. Recombinant Human Serum Albumins Coating of Medical Devices , by Region USD Million (2016-2021)
  • Table 9. Recombinant Human Serum Albumins Vitro Fertilization , by Region USD Million (2016-2021)
  • Table 10. Recombinant Human Serum Albumins Cosmetic , by Region USD Million (2016-2021)
  • Table 11. Recombinant Human Serum Albumins Others , by Region USD Million (2016-2021)
  • Table 12. Recombinant Human Serum Albumins: by End-Use(USD Million)
  • Table 13. Recombinant Human Serum Albumins Hospitals , by Region USD Million (2016-2021)
  • Table 14. Recombinant Human Serum Albumins Clinics , by Region USD Million (2016-2021)
  • Table 15. Recombinant Human Serum Albumins Biopharming , by Region USD Million (2016-2021)
  • Table 16. South America Recombinant Human Serum Albumins, by Country USD Million (2016-2021)
  • Table 17. South America Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 18. South America Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 19. South America Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 20. Brazil Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 21. Brazil Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 22. Brazil Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 23. Argentina Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 24. Argentina Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 25. Argentina Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 26. Rest of South America Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 27. Rest of South America Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 28. Rest of South America Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 29. Asia Pacific Recombinant Human Serum Albumins, by Country USD Million (2016-2021)
  • Table 30. Asia Pacific Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 31. Asia Pacific Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 33. China Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 34. China Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 35. China Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 36. Japan Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 37. Japan Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 38. Japan Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 39. India Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 40. India Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 41. India Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 42. South Korea Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 43. South Korea Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 44. South Korea Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 45. Taiwan Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 46. Taiwan Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 47. Taiwan Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 48. Australia Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 49. Australia Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 50. Australia Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 54. Europe Recombinant Human Serum Albumins, by Country USD Million (2016-2021)
  • Table 55. Europe Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 56. Europe Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 57. Europe Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 58. Germany Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 59. Germany Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 60. Germany Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 61. France Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 62. France Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 63. France Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 64. Italy Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 65. Italy Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 66. Italy Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 67. United Kingdom Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 68. United Kingdom Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 69. United Kingdom Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 70. Netherlands Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 71. Netherlands Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 72. Netherlands Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 73. Rest of Europe Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 74. Rest of Europe Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 75. Rest of Europe Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 76. MEA Recombinant Human Serum Albumins, by Country USD Million (2016-2021)
  • Table 77. MEA Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 78. MEA Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 79. MEA Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 80. Middle East Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 81. Middle East Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 82. Middle East Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 83. Africa Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 84. Africa Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 85. Africa Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 86. North America Recombinant Human Serum Albumins, by Country USD Million (2016-2021)
  • Table 87. North America Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 88. North America Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 89. North America Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 90. United States Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 91. United States Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 92. United States Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 93. Canada Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 94. Canada Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 95. Canada Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 96. Mexico Recombinant Human Serum Albumins, by Type USD Million (2016-2021)
  • Table 97. Mexico Recombinant Human Serum Albumins, by Application USD Million (2016-2021)
  • Table 98. Mexico Recombinant Human Serum Albumins, by End-Use USD Million (2016-2021)
  • Table 99. Recombinant Human Serum Albumins Sales: by Type(ml)
  • Table 100. Recombinant Human Serum Albumins Sales OsrHSA , by Region ml (2016-2021)
  • Table 101. Recombinant Human Serum Albumins Sales ScrHSA , by Region ml (2016-2021)
  • Table 102. Recombinant Human Serum Albumins Sales: by Application(ml)
  • Table 103. Recombinant Human Serum Albumins Sales Drug Formulation , by Region ml (2016-2021)
  • Table 104. Recombinant Human Serum Albumins Sales Pharmaceuticals , by Region ml (2016-2021)
  • Table 105. Recombinant Human Serum Albumins Sales Diagnostics , by Region ml (2016-2021)
  • Table 106. Recombinant Human Serum Albumins Sales Coating of Medical Devices , by Region ml (2016-2021)
  • Table 107. Recombinant Human Serum Albumins Sales Vitro Fertilization , by Region ml (2016-2021)
  • Table 108. Recombinant Human Serum Albumins Sales Cosmetic , by Region ml (2016-2021)
  • Table 109. Recombinant Human Serum Albumins Sales Others , by Region ml (2016-2021)
  • Table 110. Recombinant Human Serum Albumins Sales: by End-Use(ml)
  • Table 111. Recombinant Human Serum Albumins Sales Hospitals , by Region ml (2016-2021)
  • Table 112. Recombinant Human Serum Albumins Sales Clinics , by Region ml (2016-2021)
  • Table 113. Recombinant Human Serum Albumins Sales Biopharming , by Region ml (2016-2021)
  • Table 114. South America Recombinant Human Serum Albumins Sales, by Country ml (2016-2021)
  • Table 115. South America Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 116. South America Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 117. South America Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 118. Brazil Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 119. Brazil Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 120. Brazil Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 121. Argentina Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 122. Argentina Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 123. Argentina Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 124. Rest of South America Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 125. Rest of South America Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 126. Rest of South America Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 127. Asia Pacific Recombinant Human Serum Albumins Sales, by Country ml (2016-2021)
  • Table 128. Asia Pacific Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 129. Asia Pacific Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 130. Asia Pacific Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 131. China Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 132. China Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 133. China Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 134. Japan Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 135. Japan Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 136. Japan Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 137. India Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 138. India Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 139. India Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 140. South Korea Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 141. South Korea Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 142. South Korea Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 143. Taiwan Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 144. Taiwan Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 145. Taiwan Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 146. Australia Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 147. Australia Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 148. Australia Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 149. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 150. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 151. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 152. Europe Recombinant Human Serum Albumins Sales, by Country ml (2016-2021)
  • Table 153. Europe Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 154. Europe Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 155. Europe Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 156. Germany Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 157. Germany Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 158. Germany Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 159. France Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 160. France Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 161. France Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 162. Italy Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 163. Italy Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 164. Italy Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 165. United Kingdom Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 166. United Kingdom Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 167. United Kingdom Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 168. Netherlands Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 169. Netherlands Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 170. Netherlands Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 171. Rest of Europe Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 172. Rest of Europe Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 173. Rest of Europe Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 174. MEA Recombinant Human Serum Albumins Sales, by Country ml (2016-2021)
  • Table 175. MEA Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 176. MEA Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 177. MEA Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 178. Middle East Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 179. Middle East Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 180. Middle East Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 181. Africa Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 182. Africa Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 183. Africa Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 184. North America Recombinant Human Serum Albumins Sales, by Country ml (2016-2021)
  • Table 185. North America Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 186. North America Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 187. North America Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 188. United States Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 189. United States Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 190. United States Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 191. Canada Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 192. Canada Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 193. Canada Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 194. Mexico Recombinant Human Serum Albumins Sales, by Type ml (2016-2021)
  • Table 195. Mexico Recombinant Human Serum Albumins Sales, by Application ml (2016-2021)
  • Table 196. Mexico Recombinant Human Serum Albumins Sales, by End-Use ml (2016-2021)
  • Table 197. Recombinant Human Serum Albumins: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Recombinant Human Serum Albumins: by Type(USD Million)
  • Table 208. Recombinant Human Serum Albumins OsrHSA , by Region USD Million (2022-2027)
  • Table 209. Recombinant Human Serum Albumins ScrHSA , by Region USD Million (2022-2027)
  • Table 210. Recombinant Human Serum Albumins: by Application(USD Million)
  • Table 211. Recombinant Human Serum Albumins Drug Formulation , by Region USD Million (2022-2027)
  • Table 212. Recombinant Human Serum Albumins Pharmaceuticals , by Region USD Million (2022-2027)
  • Table 213. Recombinant Human Serum Albumins Diagnostics , by Region USD Million (2022-2027)
  • Table 214. Recombinant Human Serum Albumins Coating of Medical Devices , by Region USD Million (2022-2027)
  • Table 215. Recombinant Human Serum Albumins Vitro Fertilization , by Region USD Million (2022-2027)
  • Table 216. Recombinant Human Serum Albumins Cosmetic , by Region USD Million (2022-2027)
  • Table 217. Recombinant Human Serum Albumins Others , by Region USD Million (2022-2027)
  • Table 218. Recombinant Human Serum Albumins: by End-Use(USD Million)
  • Table 219. Recombinant Human Serum Albumins Hospitals , by Region USD Million (2022-2027)
  • Table 220. Recombinant Human Serum Albumins Clinics , by Region USD Million (2022-2027)
  • Table 221. Recombinant Human Serum Albumins Biopharming , by Region USD Million (2022-2027)
  • Table 222. South America Recombinant Human Serum Albumins, by Country USD Million (2022-2027)
  • Table 223. South America Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 224. South America Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 225. South America Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 226. Brazil Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 227. Brazil Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 228. Brazil Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 229. Argentina Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 230. Argentina Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 231. Argentina Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 232. Rest of South America Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 233. Rest of South America Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 234. Rest of South America Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 235. Asia Pacific Recombinant Human Serum Albumins, by Country USD Million (2022-2027)
  • Table 236. Asia Pacific Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 237. Asia Pacific Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 238. Asia Pacific Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 239. China Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 240. China Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 241. China Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 242. Japan Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 243. Japan Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 244. Japan Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 245. India Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 246. India Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 247. India Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 248. South Korea Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 249. South Korea Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 250. South Korea Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 251. Taiwan Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 252. Taiwan Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 253. Taiwan Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 254. Australia Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 255. Australia Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 256. Australia Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 257. Rest of Asia-Pacific Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 258. Rest of Asia-Pacific Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 259. Rest of Asia-Pacific Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 260. Europe Recombinant Human Serum Albumins, by Country USD Million (2022-2027)
  • Table 261. Europe Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 262. Europe Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 263. Europe Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 264. Germany Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 265. Germany Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 266. Germany Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 267. France Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 268. France Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 269. France Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 270. Italy Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 271. Italy Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 272. Italy Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 273. United Kingdom Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 274. United Kingdom Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 275. United Kingdom Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 276. Netherlands Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 277. Netherlands Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 278. Netherlands Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 279. Rest of Europe Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 280. Rest of Europe Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 281. Rest of Europe Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 282. MEA Recombinant Human Serum Albumins, by Country USD Million (2022-2027)
  • Table 283. MEA Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 284. MEA Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 285. MEA Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 286. Middle East Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 287. Middle East Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 288. Middle East Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 289. Africa Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 290. Africa Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 291. Africa Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 292. North America Recombinant Human Serum Albumins, by Country USD Million (2022-2027)
  • Table 293. North America Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 294. North America Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 295. North America Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 296. United States Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 297. United States Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 298. United States Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 299. Canada Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 300. Canada Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 301. Canada Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 302. Mexico Recombinant Human Serum Albumins, by Type USD Million (2022-2027)
  • Table 303. Mexico Recombinant Human Serum Albumins, by Application USD Million (2022-2027)
  • Table 304. Mexico Recombinant Human Serum Albumins, by End-Use USD Million (2022-2027)
  • Table 305. Recombinant Human Serum Albumins Sales: by Type(ml)
  • Table 306. Recombinant Human Serum Albumins Sales OsrHSA , by Region ml (2022-2027)
  • Table 307. Recombinant Human Serum Albumins Sales ScrHSA , by Region ml (2022-2027)
  • Table 308. Recombinant Human Serum Albumins Sales: by Application(ml)
  • Table 309. Recombinant Human Serum Albumins Sales Drug Formulation , by Region ml (2022-2027)
  • Table 310. Recombinant Human Serum Albumins Sales Pharmaceuticals , by Region ml (2022-2027)
  • Table 311. Recombinant Human Serum Albumins Sales Diagnostics , by Region ml (2022-2027)
  • Table 312. Recombinant Human Serum Albumins Sales Coating of Medical Devices , by Region ml (2022-2027)
  • Table 313. Recombinant Human Serum Albumins Sales Vitro Fertilization , by Region ml (2022-2027)
  • Table 314. Recombinant Human Serum Albumins Sales Cosmetic , by Region ml (2022-2027)
  • Table 315. Recombinant Human Serum Albumins Sales Others , by Region ml (2022-2027)
  • Table 316. Recombinant Human Serum Albumins Sales: by End-Use(ml)
  • Table 317. Recombinant Human Serum Albumins Sales Hospitals , by Region ml (2022-2027)
  • Table 318. Recombinant Human Serum Albumins Sales Clinics , by Region ml (2022-2027)
  • Table 319. Recombinant Human Serum Albumins Sales Biopharming , by Region ml (2022-2027)
  • Table 320. South America Recombinant Human Serum Albumins Sales, by Country ml (2022-2027)
  • Table 321. South America Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 322. South America Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 323. South America Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 324. Brazil Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 325. Brazil Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 326. Brazil Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 327. Argentina Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 328. Argentina Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 329. Argentina Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 330. Rest of South America Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 331. Rest of South America Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 332. Rest of South America Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 333. Asia Pacific Recombinant Human Serum Albumins Sales, by Country ml (2022-2027)
  • Table 334. Asia Pacific Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 335. Asia Pacific Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 336. Asia Pacific Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 337. China Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 338. China Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 339. China Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 340. Japan Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 341. Japan Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 342. Japan Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 343. India Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 344. India Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 345. India Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 346. South Korea Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 347. South Korea Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 348. South Korea Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 349. Taiwan Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 350. Taiwan Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 351. Taiwan Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 352. Australia Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 353. Australia Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 354. Australia Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 355. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 356. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 357. Rest of Asia-Pacific Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 358. Europe Recombinant Human Serum Albumins Sales, by Country ml (2022-2027)
  • Table 359. Europe Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 360. Europe Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 361. Europe Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 362. Germany Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 363. Germany Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 364. Germany Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 365. France Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 366. France Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 367. France Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 368. Italy Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 369. Italy Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 370. Italy Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 371. United Kingdom Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 372. United Kingdom Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 373. United Kingdom Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 374. Netherlands Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 375. Netherlands Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 376. Netherlands Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 377. Rest of Europe Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 378. Rest of Europe Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 379. Rest of Europe Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 380. MEA Recombinant Human Serum Albumins Sales, by Country ml (2022-2027)
  • Table 381. MEA Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 382. MEA Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 383. MEA Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 384. Middle East Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 385. Middle East Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 386. Middle East Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 387. Africa Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 388. Africa Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 389. Africa Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 390. North America Recombinant Human Serum Albumins Sales, by Country ml (2022-2027)
  • Table 391. North America Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 392. North America Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 393. North America Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 394. United States Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 395. United States Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 396. United States Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 397. Canada Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 398. Canada Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 399. Canada Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 400. Mexico Recombinant Human Serum Albumins Sales, by Type ml (2022-2027)
  • Table 401. Mexico Recombinant Human Serum Albumins Sales, by Application ml (2022-2027)
  • Table 402. Mexico Recombinant Human Serum Albumins Sales, by End-Use ml (2022-2027)
  • Table 403. Recombinant Human Serum Albumins: by Type(USD/Units)
  • Table 404. Research Programs/Design for This Report
  • Table 405. Key Data Information from Secondary Sources
  • Table 406. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Human Serum Albumins: by Type USD Million (2016-2021)
  • Figure 5. Global Recombinant Human Serum Albumins: by Application USD Million (2016-2021)
  • Figure 6. Global Recombinant Human Serum Albumins: by End-Use USD Million (2016-2021)
  • Figure 7. South America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 8. Asia Pacific Recombinant Human Serum Albumins Share (%), by Country
  • Figure 9. Europe Recombinant Human Serum Albumins Share (%), by Country
  • Figure 10. MEA Recombinant Human Serum Albumins Share (%), by Country
  • Figure 11. North America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 12. Global Recombinant Human Serum Albumins: by Type ml (2016-2021)
  • Figure 13. Global Recombinant Human Serum Albumins: by Application ml (2016-2021)
  • Figure 14. Global Recombinant Human Serum Albumins: by End-Use ml (2016-2021)
  • Figure 15. South America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 16. Asia Pacific Recombinant Human Serum Albumins Share (%), by Country
  • Figure 17. Europe Recombinant Human Serum Albumins Share (%), by Country
  • Figure 18. MEA Recombinant Human Serum Albumins Share (%), by Country
  • Figure 19. North America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 20. Global Recombinant Human Serum Albumins: by Type USD/Units (2016-2021)
  • Figure 21. Global Recombinant Human Serum Albumins share by Players 2021 (%)
  • Figure 22. Global Recombinant Human Serum Albumins share by Players (Top 3) 2021(%)
  • Figure 23. Global Recombinant Human Serum Albumins share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Albumedix (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Albumedix (United Kingdom) Revenue: by Geography 2021
  • Figure 27. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck (United States) Revenue: by Geography 2021
  • Figure 29. Ventria (InVitria) (United States) Revenue, Net Income and Gross profit
  • Figure 30. Ventria (InVitria) (United States) Revenue: by Geography 2021
  • Figure 31. Proteintech Group (United States) Revenue, Net Income and Gross profit
  • Figure 32. Proteintech Group (United States) Revenue: by Geography 2021
  • Figure 33. Wuhan Healthgen Biotechnology Corp. (China) Revenue, Net Income and Gross profit
  • Figure 34. Wuhan Healthgen Biotechnology Corp. (China) Revenue: by Geography 2021
  • Figure 35. HiMedia Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 36. HiMedia Laboratories (India) Revenue: by Geography 2021
  • Figure 37. Biorbyt Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Biorbyt Ltd. (United Kingdom) Revenue: by Geography 2021
  • Figure 39. Aspira Chemical (United States) Revenue, Net Income and Gross profit
  • Figure 40. Aspira Chemical (United States) Revenue: by Geography 2021
  • Figure 41. Lazuline (India) Revenue, Net Income and Gross profit
  • Figure 42. Lazuline (India) Revenue: by Geography 2021
  • Figure 43. Global Recombinant Human Serum Albumins: by Type USD Million (2022-2027)
  • Figure 44. Global Recombinant Human Serum Albumins: by Application USD Million (2022-2027)
  • Figure 45. Global Recombinant Human Serum Albumins: by End-Use USD Million (2022-2027)
  • Figure 46. South America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 47. Asia Pacific Recombinant Human Serum Albumins Share (%), by Country
  • Figure 48. Europe Recombinant Human Serum Albumins Share (%), by Country
  • Figure 49. MEA Recombinant Human Serum Albumins Share (%), by Country
  • Figure 50. North America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 51. Global Recombinant Human Serum Albumins: by Type ml (2022-2027)
  • Figure 52. Global Recombinant Human Serum Albumins: by Application ml (2022-2027)
  • Figure 53. Global Recombinant Human Serum Albumins: by End-Use ml (2022-2027)
  • Figure 54. South America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 55. Asia Pacific Recombinant Human Serum Albumins Share (%), by Country
  • Figure 56. Europe Recombinant Human Serum Albumins Share (%), by Country
  • Figure 57. MEA Recombinant Human Serum Albumins Share (%), by Country
  • Figure 58. North America Recombinant Human Serum Albumins Share (%), by Country
  • Figure 59. Global Recombinant Human Serum Albumins: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Albumedix (United Kingdom)
  • Merck (United States)
  • Ventria (InVitria) (United States)
  • Proteintech Group (United States)
  • Wuhan Healthgen Biotechnology Corp. (China)
  • HiMedia Laboratories (India)
  • Biorbyt Ltd. (United Kingdom)
  • Aspira Chemical (United States)
  • Lazuline (India)
Select User Access Type

Key Highlights of Report


Jan 2022 124 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Human Serum Albumins Market Quantitative research analysis
Global Recombinant Human Serum Albumins Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Recombinant Human Serum Albumins Market are Albumedix (United Kingdom), Merck (United States), Ventria (InVitria) (United States), Proteintech Group (United States), Wuhan Healthgen Biotechnology Corp. (China), HiMedia Laboratories (India), Biorbyt Ltd. (United Kingdom), Aspira Chemical (United States) and Lazuline (India) etc.
Human serum albumin (HSA) is the richest protein found in human blood plasma which is produced in the liver. The biological purposes of albumin include and transportation & metabolization of endogenous, normalization of the colloidal osmotic blood pressure and exogenous molecules e.g. fatty acids, amino acids, steroids, hormones, and pharmaceutical drugs. rHSA is plant-derived (rice-based), which reduces the risk of bacterial and viral infections. Additionally, the greater consistency of rHSA saves time while providing better performance. The annual demand for therapeutic human serum albumin (HSA) is predictable to be more than 500 metric tons worldwide. As a major protein in the human body, HSA plays a vital role in many physiological processes, including the maintenance of oncotic pressure and the transportation of various biomolecules and pharmaceuticals.

Know More About Global Recombinant Human Serum Albumins Market Report?

Have a Query? Click Here

Other Related Reports

Naproxen Comprehensive Study by Type (Tablet, Capsule, Other), Application (Rheumatoid Arthritis, Gout, Other), Distribution Channels (Pharmaceutical Stores, Clinics, Others) Players and Region - Glo...
$ 3500
Erythromycin Comprehensive Study by Form (Gel, Tablet, Topical Solution, Ointment, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Therapeutic Indications (...
$ 3650
Dystonia Drugs Comprehensive Study by Route of Administration (Oral, Injectable), Drug Types (Capsules, Tablets, Other), Dystonias syndromes (Blepharospasm, Cervical dystonia, Cranial dystonia, Tardi...
$ 3750
Vertigo Drugs Comprehensive Study by Route of Administration (Oral, Injection), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Class (Anticholinergics, Antihistamines, Be...
$ 3650
Nano Colloidal Silver Comprehensive Study by Type (10ppm Colloidal Silver, 20ppm Colloidal Silver, 22ppm Colloidal Silver, 30ppm Colloidal Silver, Others), Application (Deodorant, Epidemic Prevention...
$ 3450
Psychotropic Drug Comprehensive Study by End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital pharmacies, Drug Stores, Retail Stores, E-Commerce), Drug Class (Anti-Depressants, Anti...
$ 3450